Filtered By:
Cancer: Squamous Cell Carcinoma
Drug: Docetaxel

This page shows you your search results in order of date.

Order by Relevance | Date

Total 5 results found since Jan 2013.

Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression
Conclusions MDSC are major players in the immunosuppressive scenario in cancer, thanks to their phenotype heterogeneity and critical interaction with several innate immune cells, thus representing a crucial target in oncology. Here we reviewed the interactions of MDSCs with NK cells. The contribution of key cytokines, chemokines and mediators active in this process have been discussed. We also described the contribution of MDSC on angiogenesis directly or indirectly through interactions with NK and immunosuppressive activities. A parallel of the cancer associated to the decidual counterpart of these cells is discussed, a...
Source: Frontiers in Immunology - April 17, 2019 Category: Allergy & Immunology Source Type: research

Livin enhances chemoresistance in head and neck squamous cell carcinoma.
In conclusion, our results suggest that siRNA-mediated Livin knockdown enhanced the chemosensitivity of the three HNSCC cell lines to cisplatin, 5-FU and docetaxel. Although further investigations are required to support these findings, our results demonstrated that novel therapeutic strategies with combined use of siRNA targeting Livin and chemotherapeutic agents may have applications in the treatment of advanced HNSCC. PMID: 28440463 [PubMed - as supplied by publisher]
Source: Oncology Reports - April 27, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

ABCB1 Is Upregulated in Acquisition of Taxane Resistance: Lessons from Esophageal Squamous Cell Carcinoma Cell Lines.
In conclusion, we propose that ABCB1 might play a pivotal role in acquisition of taxane resistance and could be a promising target for treatment of patients with esophageal cancer after acquisition of taxane resistance. PMID: 27941276 [PubMed - in process]
Source: The Tohoku Journal of Experimental Medicine - December 14, 2016 Category: Research Authors: Wang R, Sumarpo A, Saiki Y, Chen N, Sunamura M, Horii A Tags: Tohoku J Exp Med Source Type: research

Abstract 1724: Integrated functional RNAi screening and structural genomics identify inverse co-modulators of TP53 family and NF-{kappa}B transitional activation as potential therapeutic targets in head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide with a 50-60% mortality rate. Deregulation of p53 family members in HNSCC occurs in over 90% of cases, preventing transcription of growth arrest and apoptosis genes. Conversely, members of the NF-κB/REL family are aberrantly activated in about ∼70% of cases, and drive expression of pro-proliferation, inflammation, angiogenesis, and therapeutic resistance genes. The function of different TP53 and NF-κB family members are inversely modulated within two major subsets of HNSCC, suggesting that common molecules and pathways coordinate this...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Saleh, A., Cornelius, S., Martin, S., Ormanoglu, P., Cheng, H., Das, R., Yang, X., Chen, Z., Van Waes, C. Tags: Experimental and Molecular Therapeutics Source Type: research

Abstract 2623: PI3K/mTOR dual inhibitor PF-5212384 inhibits aberrant NF-kB activation and exhibits activity in combination with MEK inhibitor PD-325901 and docetaxel in human head and neck squamous cell carcinoma
In this study, we determined the effects of the novel PI3K-mTOR inhibitor PF-5212384 (PF-384) on molecular targets and HNSCC growth in preclinical models. PF-384 IC50s of 0.75nM-133nM were found in 12 HNSCC lines by XTT cell density assays and treatment resulted in increased sub-G0 cell death and G0/G1 phase blockade by DNA flow cytometry. PF-384 strongly inhibited direct targets of PI3K-mTOR, aberrant NF-kB transactivation and induced cytokines, but only partially inhibited MEK pathway targets. Transient siRNA knockdown of PIK3CA inhibited NF-kB activity, supporting PI3K-mTOR as an important driver and target for inhibiti...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Mohan, S., Broek, R. J. V., Saleh, A. D., Pierce, M. L., Coupar, J. F., Eytan, D. F., Chen, Z., Waes, C. V. Tags: Experimental and Molecular Therapeutics Source Type: research